EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

David A Sallman iD, Rami S Komrokji iD, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero, Ramy Rahmé, Eric S Winer, Jacqueline Lehmann-Che, Gail J Roboz, Isabelle Madelaine, Mikkael A Sekeres, Pierre Peterlin und 21 weitere

HemaSphere · 2025-07 · 9 (7)

DOI: 10.1002/hem3.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 13.07.2025. Verfasst von David A Sallman und 32 weiteren Autor:innen. Beteiligte Einrichtung: Malignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 gene mutations (m TP53 ) represent a distinct molecular cohort with poor outcomes. Eprenetapopt (APR‐246) is a novel, first‐in‐class small molecule that reactivates p53 and targets cellular redox balance, ultimately inducing apoptosis and ferroptosis in m TP53 cancer cells. This is a multicenter, international collaboration of the US myelodysplastic syndromes/neoplasms (MDS) clinical research symposium and the Groupe Francophone des Myelodysplasies (GFM) of hypomethylating agents‐naïve m TP53 higher risk MDS and oligoblastic acute myeloid leukemia (AML; ≤30% blasts; NCT03072043/NCT03588078). Patients received eprenetapopt 4500 mg iv (Days 1–4) + azacitidine 75 mg/m 2 sc/iv × 7 days in 28‐day cycles. The primary objective was the complete remission (CR) rate by International Working Group (IWG) 2006 criteria. In total, 100 patients were enrolled with a median age of 68 years (34–87; 47% male). Febrile neutropenia occurred in 37% of patients. Thirty‐ and 60‐day mortality was 1% and 7%, respectively. By intention‐to‐treat, overall response rate by IWG was 69% with 41% CR. The median duration of CR was 10.2 months (95% CI 8.7–11.8). With a median follow‐up of 52 months, median overall survival (OS) was 11.8 months (95% CI 9.4–14.3). Although allogeneic hematopoietic cell transplantation (allo‐HCT) was borderline predictive of OS in the overall cohort by landmark analysis (14.7 vs. 14.4 months; P = 0.046), OS was significantly improved in allo‐HCT patients based on CR/ TP53 next‐generation sequencing (NGS) negativity (P = 0.00085; 2‐year OS of 54%). In this international, combined analysis of Phase 2 eprenetapopt + azacitidine patients, the combination was well‐tolerated with synergistic response rates in m TP53 MDS/AML. Quality of response and NGS negativity strongly predicted OS, particularly in the setting of allo‐HCT, validating NGS clearance as a critical biomarker of allo‐HCT outcomes in m TP53 patients.

Autor:innen und Institutionen

  • Malignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
  • Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA.
  • Groupe Francophone de Myelodysplasies, GFM Paris France.
  • Hematology Department Hospital Saint Louis, APHP Paris France.
  • Department of Leukemia MD Anderson Cancer Center Houston Texas USA.
  • Dana Farber Cancer Institute Boston Massachusetts USA.

ORCID-Profile: David A Sallman, Rami S Komrokji, Thomas Cluzeau

Zitieren

APA

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia-Manero, G., Rahmé, R., Winer, E. S., Lehmann-Che, J., Roboz, G. J., Madelaine, I., Sekeres, M. A., Peterlin, P., Chan, O., Beyne-Rauzy, O., Kuykendall, A., Recher, C., McLemore, A., Stamatoullas, A., Zhang, L., …, & Cluzeau, T. (2025). Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. HemaSphere, 9(7). https://doi.org/10.1002/hem3.70164

Vancouver

Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahmé R, et al. Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. HemaSphere. 2025;9(7). doi:10.1002/hem3.70164

BibTeX
@article{Sallman2025,
  author = {Sallman, David A and Komrokji, Rami S and Dezern, Amy E and Sebert, Marie and Garcia-Manero, Guillermo and Rahmé, Ramy and Winer, Eric S and Lehmann-Che, Jacqueline and Roboz, Gail J and Madelaine, Isabelle and Sekeres, Mikkael A and Peterlin, Pierre and Chan, Onyee and Beyne-Rauzy, Odile and Kuykendall, Andrew and Recher, Christian and McLemore, Amy and Stamatoullas, Aspasia and Zhang, Ling and Willems, Lise and Mo, Qianxing and Raffoux, Emmanuel and Nardelli, Lisa and Berthon, Céline and Al Ali, Najla H and Quesnel, Bruno and Padron, Eric and Kantarjian, Hagop M and List, Alan F and Ades, Lionel and Lancet, Jeffrey E and Fenaux, Pierre and Cluzeau, Thomas},
  title = {Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML},
  journal = {HemaSphere},
  year = {2025},
  volume = {9},
  number = {7},
  doi = {10.1002/hem3.70164}
}
Kostenlos starten →